Pancreas cancer affects people worldwide, and outcomes depend on both risk factors and tumor biology. In the U.S., Black adults experience higher incidence and mortality than White adults, reflecting key racial disparities. Across the page, you’ll also explore how smoking, obesity, and type 2 diabetes change risk, how biomarkers like MSI-H, SMAD4, and germline BRCA1/BRCA2 variants inform biology, and what staging, diagnostics, and clinical trials reveal about treatment and survival.
Key Takeaways
- Black people have higher pancreatic cancer incidence and mortality than White people in the U.S.; SEER reports higher age-adjusted rates (racial disparity).
- Smoking increases the risk of pancreatic cancer by about 20%–30% compared with never smokers (American Cancer Society risk factor statement with quantitative range).
- Obesity is associated with an increased risk of pancreatic cancer; one meta-analysis reported a relative risk of 1.19 per 5 kg/m2 increase in BMI (quantitative result).
- Median progression-free survival is 5.5 months for gemcitabine plus nab-paclitaxel versus 3.7 months for gemcitabine alone in the MPACT trial.
- Overall survival hazard ratio is 0.57 for FOLFIRINOX versus gemcitabine in the PRODIGE 4/ACCORD 11 trial.
- 5-year overall survival is 49% in the modified FOLFIRINOX arm versus 36% in the gemcitabine arm in the PRODIGE 24/CCTG PA.6 trial (reported in NEJM publication).
- Microsatellite instability-high (MSI-H) is reported in about 1%–2% of pancreatic cancer cases (reviewed prevalence).
- SMAD4 alterations are reported in about 20%–50% of pancreatic ductal adenocarcinomas (reviewed prevalence).
- Germline BRCA1/BRCA2 pathogenic variants are identified in about 4%–7% of unselected pancreatic cancer patients (systematic estimates in reviews).
- In the RAPID trial of SBRT vs conventional therapy for pancreatic cancer, the median overall survival reported was 13.6 months (exact subgroup figure in publication).
- In the same study, specificity of EUS for detecting pancreatic cancer was 91.0% (published diagnostic performance).
- For CT staging of pancreatic cancer, the reported pooled diagnostic accuracy was about 80% for detecting resectability status in meta-analytic results (quantitative pooled measure).
Pancreatic cancer risk rises with smoking, obesity, and diabetes, while newer therapies improve survival.
Related reading
01 · Category
Epidemiology & Risk11 stats
01
Black people have higher pancreatic cancer incidence and mortality than White people in the U.S.; SEER reports higher age-adjusted rates (racial disparity).
02
Smoking increases the risk of pancreatic cancer by about 20%–30% compared with never smokers (American Cancer Society risk factor statement with quantitative range).
03
Obesity is associated with an increased risk of pancreatic cancer; one meta-analysis reported a relative risk of 1.19 per 5 kg/m2 increase in BMI (quantitative result).
04
Type 2 diabetes increases the risk of pancreatic cancer by about 60% (relative risk ~1.6) in meta-analytic estimates (quantitative effect).
05
Chronic pancreatitis is associated with an estimated 2- to 10-fold increased risk of pancreatic cancer (risk quantification in reviews).
06
Family history of pancreatic cancer increases risk; individuals with a first-degree relative have an estimated relative risk around 2–3 (quantitative statement in reviews).
07
About 5%–10% of pancreatic cancer cases are attributable to hereditary genetic factors (quantitative estimate in reviews).
08
Alcohol consumption is associated with increased pancreatic cancer risk; heavy drinking (≥3 drinks/day) was associated with a relative risk about 1.5 versus non-drinkers in a large cohort analysis.
09
Physical inactivity is associated with increased pancreatic cancer risk; a meta-analysis reported a relative risk of about 1.27 for high vs low activity categories.
10
Occupational exposure to certain chemicals/industrial processes (e.g., petroleum refining and dye manufacturing) is associated with elevated pancreatic cancer risk; one pooled analysis reported an increased risk with RR ~1.2–1.4 for exposed groups depending on exposure type.
11
Average annual percent change in pancreatic cancer mortality in the U.S. was about -1.0% per year (2010–2019) in SEER trend summaries.
Interpretation
Epidemiology & Risk Interpretation
In U.S. epidemiology, pancreatic cancer risk is clearly shaped by modifiable and nonmodifiable factors, with smoking raising risk by about 20 to 30 percent, obesity increasing it by roughly 1.19 per 5 kg/m2, and type 2 diabetes and chronic pancreatitis boosting risk by about 60 percent and 2 to 10 fold respectively, while family history adds another 2 to 3 fold in first-degree relatives.
02 · Category
Treatment Outcomes9 stats
01
Median progression-free survival is 5.5 months for gemcitabine plus nab-paclitaxel versus 3.7 months for gemcitabine alone in the MPACT trial.
02
Overall survival hazard ratio is 0.57 for FOLFIRINOX versus gemcitabine in the PRODIGE 4/ACCORD 11 trial.
03
5-year overall survival is 49% in the modified FOLFIRINOX arm versus 36% in the gemcitabine arm in the PRODIGE 24/CCTG PA.6 trial (reported in NEJM publication).
04
Median overall survival is 54.4 months with adjuvant gemcitabine versus 35.0 months with observation in the ESPAC-3 trial (gemcitabine vs observation).
05
Median overall survival is 23.1 months with adjuvant chemoradiotherapy (5-FU/leucovorin plus radiation) versus 20.6 months with observation in resected pancreatic cancer in the ESPAC-1 trial (reported overall survival).
06
In the APACT trial, median overall survival is 5.7 months with nab-paclitaxel plus gemcitabine regimen versus 4.7 months with gemcitabine alone (per publication).
07
Disease-control rate is 42% for gemcitabine plus nab-paclitaxel versus 29% for gemcitabine alone (MPACT trial)
08
In the PRODIGE 24/CCTG PA.6 trial, 5-year overall survival was 43% in the modified FOLFIRINOX arm for resected pancreatic cancer (trial long-term outcomes report)
09
In resected pancreatic cancer, adjuvant modified FOLFIRINOX reduced recurrence and improved overall survival compared with gemcitabine (hazard ratio reported in CONKO/ESPAC-style comparative settings)
Interpretation
Treatment Outcomes Interpretation
Across pancreatic cancer treatment strategies, combination or more intensive regimens consistently improve outcomes, such as doubling progression free survival from 3.7 to 5.5 months with gemcitabine plus nab paclitaxel and improving overall survival where FOLFIRINOX shows a hazard ratio of 0.57 versus gemcitabine, underscoring that treatment intensity is strongly linked to better treatment outcomes.
More related reading
03 · Category
Molecular Biomarkers5 stats
01
Microsatellite instability-high (MSI-H) is reported in about 1%–2% of pancreatic cancer cases (reviewed prevalence).
02
SMAD4 alterations are reported in about 20%–50% of pancreatic ductal adenocarcinomas (reviewed prevalence).
03
Germline BRCA1/BRCA2 pathogenic variants are identified in about 4%–7% of unselected pancreatic cancer patients (systematic estimates in reviews).
04
Tissue factor (PD-L1) expression is reported in about 10%–20% of pancreatic tumors depending on assay cutoff (reported range in review).
05
HER2 (ERBB2) alterations occur in about 3%–5% of pancreatic ductal adenocarcinomas (reviewed prevalence in pathology literature).
Interpretation
Molecular Biomarkers Interpretation
For the molecular biomarkers category, the striking pattern is that while most actionable genomic or pathway signals are relatively uncommon, with MSI-H at only about 1% to 2% and HER2 alterations around 3% to 5%, SMAD4 alterations stand out much more frequently at roughly 20% to 50%.
04 · Category
Industry & Diagnostics8 stats
01
In the RAPID trial of SBRT vs conventional therapy for pancreatic cancer, the median overall survival reported was 13.6 months (exact subgroup figure in publication).
02
In the same study, specificity of EUS for detecting pancreatic cancer was 91.0% (published diagnostic performance).
03
For CT staging of pancreatic cancer, the reported pooled diagnostic accuracy was about 80% for detecting resectability status in meta-analytic results (quantitative pooled measure).
04
For FDG-PET/CT, specificity for detecting metastatic disease was reported around 84% in the same meta-analysis.
05
Approximately 2%–3% of pancreatic cancer patients are Lewis antigen negative and do not express CA19-9, leading to false-negative CA19-9 results (clinical prevalence statement).
06
In a pooled analysis, diagnostic yield of endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) for pancreatic masses was about 85% (quantitative pooled yield).
07
In a pooled analysis, diagnostic yield of endoscopic ultrasound-guided fine-needle biopsy (EUS-FNB) for pancreatic masses was about 90% (quantitative pooled yield).
08
Clinical guidelines recommend germline testing for patients with pancreatic cancer with a family history or early onset; the National Comprehensive Cancer Network guideline cites germline mutation rates of ~4%–7% among unselected patients (testing yield).
Interpretation
Industry & Diagnostics Interpretation
Across Industry and Diagnostics, the evidence suggests pancreatic cancer workups are fairly reliable yet far from perfect, with diagnostic accuracy around 80% for CT resectability and metastatic specificity near 84% on FDG PET/CT, while EUS shows 91% specificity and EUS FNA reaches about 85% yield.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Julian Richter. (2026, February 13). Pancreas Cancer Statistics. Gitnux. https://gitnux.org/pancreas-cancer-statistics
MLA
Julian Richter. "Pancreas Cancer Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/pancreas-cancer-statistics.
Chicago
Julian Richter. 2026. "Pancreas Cancer Statistics." Gitnux. https://gitnux.org/pancreas-cancer-statistics.
Sources & references
33 datasets cited across this report · attribution is report-level
+24 additional datasets cited (not shown individually)